Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic versus systemic plus intralesional rituximab for oral pemphigus vulgaris
IRCT20240604062002N1Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in pemphigus vulgaris (PV) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Severity of pemphigus vulgaris lesion and Patient satisfaction. Started Jul 2024; status: completed.
02
Drugs
rituximab
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on IRCT20240604062002N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240604062002N1.